Anita Afzali, MD, MPH, MHCM, FACG, AGAF

This month’s Healio Exclusive highlights an essential dialogue on gender disparities in medicine, particularly in gastroenterology, and the persistent barriers women face in achieving leadership roles.

In this Healio video exclusive, Anita Afzali, MD, and Aline Charabaty, MD, co-founders of Scrubs & Heels, encourage women in gastroenterology to create an allyship, mentorship or sponsorship to achieve successful work-life integration.

In this Healio exclusive video, Anita Afzali, MD, previews the upcoming 2023 ACG Annual Scientific Meeting, which will feature a variety of “hot topics,” including the impact of virtual reality and artificial intelligence on practice today.

Healio Gastroenterology is excited to announce the nominees for its annual Disruptive Innovators Awards in gastroenterology and hepatology.

RANCHO PALOS VERDES, Calif. — In a Healio video exclusive, Scrubs and Heels cofounders Anita Afzali, MD, and Aline Charabaty, MD, discuss the “inspiration, growth and transformation” attendees experienced at this year’s summit.

RANCHO PALOS VERDES, Calif. — During the Scrubs and Heels Summit, Anita Afzali, MD, MPH, FACG, highlighted the prospects for female gastroenterologists in administrative medicine, and the skills necessary for physician executive leadership.

MIAMI — In a Healio video exclusive, Aline Charabaty, MD, and Anita Afzali, MD, MPH, co-founders of the women-focused Scrubs & Heels Summit, recap an “extremely successful” inaugural event and share their expectations for future summits.

In this video exclusive with Healio Gastroenterology, Anita Afzali, MD, MPH, and Aline Charabaty, MD, co-founders of Scrubs and Heels, announced the Scrubs and Heels Summit.

In this video exclusive, Anita Afzali, MD, MPH, FACG, Aline Charabaty, MD and David T. Rubin, MD, highlighted how the COVID-19 pandemic changed the use of social media.

In this exclusive video, Anita Afzali, MD, director of the inflammatory bowel disease center at The Ohio State University, discusses the impact of emerging therapies in IBD.